DECIPHERA PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.42 USD | +0.24% |
|
+0.20% | +57.59% |
| May. 10 | Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 01 | North American Morning Briefing : Traders Wait for -2- | DJ |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 204M | Sales 2025 * | 264M | Capitalization | 2.19B |
|---|---|---|---|---|---|
| Net income 2024 * | -188M | Net income 2025 * | -169M | EV / Sales 2024 * | 10.8 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 8.31 x |
| P/E ratio 2024 * |
-12.3
x | P/E ratio 2025 * |
-14.4
x | Employees | 355 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 70.04% |
More Fundamentals
* Assessed data
More news
Latest transcript on Deciphera Pharmaceuticals, Inc.
More recommendations
More press releases
| 1 day | +0.24% | ||
| 1 week | +0.20% | ||
| Current month | +0.59% | ||
| 1 month | +68.90% | ||
| 3 months | +75.31% | ||
| 6 months | +118.57% | ||
| Current year | +57.59% |
1 week
25.34
25.55
1 month
14.0025.55
Current year
13.2525.55
1 year
9.9025.55
3 years
6.5138.91
5 years
6.5171.11
10 years
6.5171.11
| Managers | Title | Age | Since |
|---|---|---|---|
Steven Hoerter
CEO | Chief Executive Officer | 53 | 18-05-16 |
Tucker Kelly
DFI | Director of Finance/CFO | 53 | 15-01-31 |
Kevin Brodbeck
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Patricia Allen
BRD | Director/Board Member | 62 | 16-08-31 |
Edward Benz
BRD | Director/Board Member | 78 | 19-06-30 |
Ron Squarer
CHM | Chairman | 57 | 19-12-03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 0 M€ | 0.00% | - | |
| 0.07% | 0 M€ | 0.00% | - | |
| 0.05% | 2 M€ | -.--% | ||
| 0.04% | 234 M€ | +2.60% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 25.42 | +0.24% | 1,583,213 |
| 24-05-10 | 25.36 | -0.04% | 1,795,434 |
| 24-05-09 | 25.37 | 0.00% | 2,365,170 |
| 24-05-08 | 25.37 | -0.04% | 1,879,443 |
| 24-05-07 | 25.38 | +0.04% | 1,664,680 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotes
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.
Calendar
2024-06-20
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
25.42
USD
Average target price
26.71
USD
Spread / Average Target
+5.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +57.59% | 2.19B | |
| +5.66% | 109B | |
| +11.23% | 105B | |
| -0.38% | 22.25B | |
| -12.15% | 22.09B | |
| -7.66% | 18.68B | |
| -36.52% | 17.58B | |
| -10.09% | 16.85B | |
| +3.33% | 13.76B | |
| +36.58% | 12.46B |
- Stock Market
- Equities
- DCPH Stock
